UBS and Citi Raise Royalty Pharma Price Targets to $49 and $50
UBS upgraded Royalty Pharma to Buy on January 30, raising its price target to $49 from $38 based on royalty deals bolstering growth. Citi maintained its Buy rating on January 27, lifting its target to $50 from $48 citing beatable estimates and reduced policy risk for 2026.
1. Analyst Upgrades Elevate Price Targets
On January 30, UBS upgraded Royalty Pharma to Buy and lifted its price target to $49 from $38. Citi followed on January 27, maintaining its Buy rating and raising its target to $50 from $48.
2. Catalyst-Rich Outlook for 2026
UBS highlighted the impact of recently closed royalty deals, which are expected to drive a catalyst-rich 2026 with multiple de-risking events, potentially unlocking significant stock upside.
3. Favorable Biopharma Setup
Citi cited beatable earnings estimates and reduced industry policy risk as key drivers, suggesting that the biopharma sector’s favorable setup could support further gains in Royalty Pharma shares.